Harrow Health, Inc. (HROW)
Largest Insider Buys in Sector
HROW Stock Price History Chart
HROW Stock Performance
About Harrow Health, Inc.
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and …
Insider Activity of Harrow Health, Inc.
Over the last 12 months, insiders at Harrow Health, Inc. have bought $1.95M and sold $0 worth of Harrow Health, Inc. stock.
On average, over the past 5 years, insiders at Harrow Health, Inc. have bought $2.11M and sold $504,800 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Opaleye Management Inc. (10 percent owner) — $11.06M. BAUM MARK L (CHIEF EXECUTIVE OFFICER) — $312,930.
The last purchase of 20,000 shares for transaction amount of $199,400 was made by Opaleye Management Inc. (10 percent owner) on 2024‑04‑25.
List of Insider Buy and Sell Transactions, Harrow Health, Inc.
| 2024-04-25 | 10 percent owner | 20,000 0.0546% | $9.97 | $199,400 | +277.70% | |||
| 2024-04-24 | 10 percent owner | 8,285 0.023% | $10.15 | $84,093 | +267.62% | |||
| 2024-04-23 | 10 percent owner | 11,715 0.033% | $10.29 | $120,547 | +265.70% | |||
| 2024-04-19 | 10 percent owner | 29,400 0.084% | $10.56 | $310,391 | +258.43% | |||
| 2024-03-28 | 10 percent owner | 50,000 0.137% | $12.82 | $641,000 | +158.30% | |||
| 2024-03-22 | CHIEF EXECUTIVE OFFICER | 9,000 0.0256% | $11.59 | $104,310 | +119.64% | |||
| 2024-03-20 | 10 percent owner | 50,600 0.1322% | $9.65 | $488,290 | +138.40% | |||
| 2023-11-16 | Chief Executive Officer | 7,500 0.0201% | $8.11 | $60,825 | +45.84% | |||
| 2023-11-15 | 10 percent owner | 25,000 0.0711% | $8.03 | $200,735 | +54.74% | |||
| 2023-09-20 | 10 percent owner | 5,983 0.0175% | $14.49 | $86,710 | -9.65% | |||
| 2023-09-19 | 10 percent owner | 14,017 0.04% | $14.65 | $205,366 | -12.55% | |||
| 2023-08-14 | Chief Executive Officer | 5,800 0.0168% | $17.05 | $98,890 | -25.74% | |||
| 2023-08-14 | director | 20,000 0.0576% | $16.92 | $338,400 | -25.74% | |||
| 2022-12-22 | Chief Executive Officer | 25,000 0.0941% | $13.39 | $334,750 | +26.91% | |||
| 2022-12-22 | Chief Financial Officer | 2,500 0.0095% | $13.54 | $33,850 | +26.91% | |||
| 2022-12-22 | director | 1,860 0.007% | $13.42 | $24,961 | +26.91% | |||
| 2022-12-21 | director | 25,000 0.0932% | $13.37 | $334,250 | +25.88% | |||
| 2022-12-14 | director | 431,183 1.3468% | $10.52 | $4.54M | +34.06% | |||
| 2022-09-30 | Sale | 40,000 0.1586% | $12.62 | $504,800 | +42.42% | |||
| 2022-04-12 | 3,557 0.0131% | $6.75 | $24,004 | +61.74% |
Insider Historical Profitability
| Opaleye Management Inc. | 10 percent owner | 3815000 10.7119% | $34.22 | 29 | 0 | +26.89% |
| BAUM MARK L | CHIEF EXECUTIVE OFFICER | 2137525 6.0018% | $34.22 | 5 | 0 | +35.4% |
| Singh Juliet | CEO, Director and President | 1954125 5.4868% | $34.22 | 2 | 0 | |
| BOLL ANDREW R. | Chief Financial Officer | 255063 0.7162% | $34.22 | 2 | 0 | +35.4% |
| THORNLEY ANTHONY S | director | 60900 0.171% | $34.22 | 6 | 0 |
Institutional Investor Ownership
| Opaleye Management Inc | $51.87M | 11.08 | 3.92M | +2.63% | +$1.33M | 11.45 | |
| Private Capital Management LLC | $39.85M | 8.51 | 3.01M | +7.8% | +$2.88M | 4.73 | |
| BlackRock | $28.88M | 6.17 | 2.18M | -1.7% | -$499,829.39 | <0.01 | |
| The Vanguard Group | $24.21M | 5.17 | 1.83M | +1.18% | +$281,177.19 | <0.0001 | |
| Morgan Stanley | $12.6M | 2.69 | 952,523 | -30.31% | -$5.48M | <0.01 |